Amicus Therapeutics Announces Presentations at the 14th International Congress of Innate Errors … | New
PHILADELPHIA, Nov 22, 2021 (GLOBE NEWSWIRE) – Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters to be presented at the 14th International Congress on Innate Errors of Metabolism (ICIEM) to be held virtually and in Sydney, Australia , November 21-23, 2021.
Digital poster presentations:
Long-term multisystem efficacy with migalastat in ERT-naive and experienced patients with acceptable GLA variants Presenter: Drago Bratkovic, MD, PARC Research Clinic, Adelaide, Australia Incidence and prevalence in neonates, children and adolescents with Fabry disease: a focused literature review Presenter: Ian Keyzor, Amicus Therapeutics, Marlow, UK
Posters are available through the Investors section of the Amicus Therapeutics website at ir.amicusrx.com.
For more information on the International Congress of Inborn Errors of Metabolism 2021, please visit www.iciem2021.com.au.
About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global patient-focused biotechnology company dedicated to the discovery, development and delivery of new, high-quality drugs for people with rare metabolic diseases. With a focus on the patient, Amicus Therapeutics is committed to advancing and expanding a strong portfolio of leading, first-order or first-order drugs for rare metabolic diseases. For more information, please visit the company’s website at www.amicusrx.com and follow us on Twitter and LinkedIn.
Investors: Andrew Faughnan Executive Director, Investor Relations [email protected] (609) 662-3809
Media: Diana Moore Director of Global Corporate Affairs and Communications [email protected] (609) 662-5079
BEND – G
Copyright 2021 GlobeNewswire, Inc.